Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05254834 · ClinicalTrials.gov registry record

The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

A clinical trial of Cancer, sponsored by Freenome Holdings.

Completed
Registry status
7,435
Enrollment target
20
Study locations

NCT05254834: Completed study of Cancer, sponsored by Freenome Holdings.

NCT05254834 is a study of Cancer that has completed, run by Freenome Holdings. The registered enrollment target is 7,435 participants, above the 3,479-participant average among 615 other Cancer trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05254834, a study of Cancer, has completed, sponsored by Freenome Holdings.

COMPLETED
Registry status
7,435 participants
Enrollment target
20
Study locations

Study Summary

This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.

Primary Outcome

To compare blood samples from cancer case and non-cancer control subjects in order to develop and characterize blood-based multiomics tests in specific cancer types or in a combination of multiple cancers.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Freenome Test

Study Locations (20)

California

  • John Muir Health - Concord
  • Carbon Health - Corona
  • Miller Bioconnect - El Cajon
  • Gastroenterology and Liver Institute - Escondido
  • Women's Cancer Network - Fresno
  • San Diego Clinical Trials - La Mesa
  • Urology Alliance Clinical Research - Los Angeles
  • Mercy Cancer Center - Merced
  • Pomona Valley Hospital Medical Center/Cancer Care Center - Pomona
  • St. Mary's Medical Center - San Francisco
  • Dominican Hospital Dignity Health - Santa Cruz
  • Stockton Hematology Oncology - Stockton
  • Torrance Memorial Physician Network - Cancer Care - Torrance

Alabama

  • Central Alabama Research - Birmingham
  • Alabama Oncology - Birmingham

Florida

  • RecioMed Clinical Research - Boynton Beach
  • Mid Florida Hematology & Oncology Center - Orange City

Arizona

  • Honor Health - Scottsdale

Arkansas

  • Highlands Oncology Group - Springdale

Connecticut

  • Eastern CT Hematology and Oncology Associates - Norwich

Trial Details

FieldValue
Enrollment Target 7,435 participants
Start Date 2022-02-15
Est. Completion 2025-07-12
Freenome Holdings

5 total trials

What the finished NCT05254834 record still lists

NCT05254834 is an observational study that tracks outcomes without assigning an intervention. Its 7,435 participants enrollment target places it among the larger protocols in the corpus, above the 3,479-participant average among 615 other Cancer trials with a reported enrollment target (114% higher).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Freenome Test is the first listed.

NCT05254834 names 20 study sites across 6 states, led by California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT05254834 about?

NCT05254834 is a clinical study titled "The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening". This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.

What is the current status of trial NCT05254834?

This trial is currently completed. The enrollment target is 7,435 participants. The study started on 2022-02-15. Estimated completion is 2025-07-12.

What conditions does trial NCT05254834 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT05254834?

The interventions under investigation include: Freenome Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05254834?

This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05254834 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05254834's enrollment target sits among peer trials

7,435 36th of 615 higher than 580 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02915198 · 7,410 participants · Phase 4

    Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

  • NCT00439049 · 7,500 participants

    Substance Abuse Pre-Treatment Screening Study

  • NCT05199701 · 7,500 participants · NA

    Prospective Case Collection Study for New Mammography Technologies

  • NCT06112418 · 7,500 participants · NA

    A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05254834, the US trial registry maintained by the National Library of Medicine. NCT05254834 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.